MUC1 and breast cancer: Rahn and co-workers evaluated tumors in 71 breast cancer patients by immunohistochemical staining with mAb B27.29, specific for an epitope PDTRPAP in the tandem repeat of MUC1, and found that tumors with poor staining in the cytoplasm had a good prognosis11.